CD109 Expression in Tumor and Stromal Cells Serves as a Prognostic Biomarker for Tumor Progression and Outcome in Gallbladder Adenocarcinoma
Pathology International · 2026
DOI: 10.1111/pin.70085 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology International, 2026. Verfasst von Taro Kogami und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan. Hauptthemen laut MEDLINE: Gallbladder Neoplasms, Adenocarcinoma, Biomarkers, Tumor, Antigens, CD. Die Arbeit nennt 41 Literaturangaben. Gefördert von: 2023 Parents' Association Grant of Kitasato University School of Medicine.
Abstract (Originalsprache)
CD109 is a glycosylphosphatidylinositol‐anchored glycoprotein that is upregulated in various human cancers and exhibits tumor‐promoting effects. In this study, we investigated the role of CD109 in gallbladder adenocarcinoma (GBAC). CD109 expression in 77 resected GBAC samples was immunohistochemically evaluated. CD109 expression in tumor cells correlated with TNM stage, N factor, histological grade, lymphatic invasion, and perineural invasion and was associated with reduced disease‐free survival (DFS) and overall survival (OS). Stromal CD109 expression was detected in several cases, similar to that of α‐SMA and FAP, suggesting its presence in cancer‐associated fibroblasts. Stromal expression was also correlated with TNM stage, N factor, perineural invasion, and reduced DFS. Combined analysis of CD109 expression in tumor and stromal cells further stratified patients by prognosis. CD109 overexpression in GBAC cell lines induced the expression of the epithelial‐to‐mesenchymal transition (EMT) markers. Analyses using a public database revealed the association between CD109 and EMT‐related gene expression in biliary tract cancer cell lines. Moreover, CD109 depletion promoted enhanced transforming growth factor‐β1/Smad3 signaling and attenuated epidermal growth factor/AKT signaling in GBAC cells in a cell type‐dependent manner. Collectively, these findings suggest that CD109 may serve as a prognostic biomarker of tumor progression and outcome in GBAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
- Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
- Department of Thoracic Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
- Department of Biomedical Sciences, College of Life and Health Sciences, Chubu University, Kasugai, Japan.
ORCID-Profile: Masaaki Ichinoe, Yoshiki Murakumo
Förderung
- 2023 Parents' Association Grant of Kitasato University School of Medicine
Zitieren
APA
Kogami, T., Ichinoe, M., Sakurai, Y., Kato, T., Matsushita, M., Tamaki, A., Kesen, Y., Hayashi, S., Sanoyama, I., Numata, Y., Umezawa, A., Ichihara, M., Kusano, C., & Murakumo, Y. (2026). CD109 Expression in Tumor and Stromal Cells Serves as a Prognostic Biomarker for Tumor Progression and Outcome in Gallbladder Adenocarcinoma. Pathology International. https://doi.org/10.1111/pin.70085
Vancouver
Kogami T, Ichinoe M, Sakurai Y, Kato T, Matsushita M, Tamaki A, et al. CD109 Expression in Tumor and Stromal Cells Serves as a Prognostic Biomarker for Tumor Progression and Outcome in Gallbladder Adenocarcinoma. Pathology International. 2026. doi:10.1111/pin.70085
BibTeX
@article{Kogami2026,
author = {Kogami, Taro and Ichinoe, Masaaki and Sakurai, Yasutaka and Kato, Takuya and Matsushita, Masahiro and Tamaki, Akihiro and Kesen, Yurika and Hayashi, Shoko and Sanoyama, Itaru and Numata, Yoshiko and Umezawa, Atsuko and Ichihara, Masatoshi and Kusano, Chika and Murakumo, Yoshiki},
title = {CD109 Expression in Tumor and Stromal Cells Serves as a Prognostic Biomarker for Tumor Progression and Outcome in Gallbladder Adenocarcinoma},
journal = {Pathology International},
year = {2026},
doi = {10.1111/pin.70085}
}
EUVIMED